← Back to patent-cliff list
QLG-1194
Tier C — Watch / tradeQLG-1194
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A, DRD2
Indications (approved)：Schizophrenia
Regional status
US
-
EU
-
China
Phase III
2026-01-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of QLG-1194?
Approved indications include: Schizophrenia.
When does the QLG-1194 patent expire?
No public expiry year is available for QLG-1194 yet; this page updates once verified.
How do I get a quote for QLG-1194 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29